News

Building while battling headwinds

Dr. Don Torry’s career reads like a classic academic success story: a small-town kid from Washington, Ill., rises through the ranks to become a leading researcher in reproductive immunology. But behind each achievement lies a more complex narrative familiar to scientists: dealing with the unexpected.
News

Progress and promise: The Alzheimer’s research landscape

Smith Alzheimer's Center executive director discusses the pursuit of a cure In the last decade, Alzheimer’s disease research has gained significant momentum. Scientists are uncovering how lifestyle factors influence risk, improving blood-based biomarker testing for earlier and less invasive diagnosis, and advancing treatment options that slow disease progression. But much remains unknown. Erin Hascup, PhD, executive director of the Smith Alzheimer’s Center at SIU Medicine, shares some insights on these developments and what the future holds. What are the latest advances in Alzheimer’s research
Events

2025 Illinois Rural and Small-Town Health Summit

The 2025 Illinois Rural and Small-Town Health Summit will be held on October 15, 2025 , at the Memorial Learning Center in Springfield, Illinois . This year the summit is supported by SIU Simmons School of Law, SIU School of Medicine Department of Population Science and Policy and Institute of Rural Health, SIU School of Medicine. This year’s theme, "Health Care Workforce: Learnings and Transformation in a Post-Pandemic Environment," will focus on strengthening and sustaining the rural and small-town healthcare workforce. The event will bring together leaders from federal, state, and local
Trial
Neurology

Renaissance 2: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of SPN-817 in Adults with Focal Onset Seizures

Active recruiting

To evaluate the efficacy of SPN-817 as a treatment for adult participants with focal onset seizures.

Trial
Simmons Cancer Institute

ASND0029 "IL Believe": A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, TransCon TLR7/8 Agonist, or Other Anticancer Therapies, in

Active recruiting
This study is investigating experimental drugs TransCon IL-2 β/γ and TransCon TLR7/8 for the treatment of advanced/metastatic solid tumors (melanoma, breast cancer, cervical cancer, ovarian cancer) in adults.
Trial
Simmons Cancer Institute

KO-MEN-008: Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia

Active recruiting

Examining the safety, tolerability, and effectiveness of investigational drug ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia. The study drug will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.

News

Southern Illinois University officially among top research schools in U.S.

SIU has officially entered the ranks of the top research universities in the nation: It has been designated Research 1, or R1, in the Carnegie Classifications of Institutions of Higher Education.
Subscribe to Research